Advancements in Multisource Mpox Vaccine Supply and Promising Cancer Therapy Results
Update: 2025-10-20
Description
GeoVax Labs, Inc. is emphasizing the need for a multisource Mpox vaccine supply to combat Clade 1 cases in California, while also advancing U.S.-based continuous cell line manufacturing. Meanwhile, Kairos Pharma Ltd. has reported positive interim efficacy data for ENV-105 in men with metastatic castration-resistant prostate cancer, showing promising results in a Phase 2 trial.
Comments
In Channel



